The gastrointestinal side-effect profile of retatrutide observed in phase 2 trials is broadly consistent with other GLP-1-based therapies, such as semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro), though retatrutide's additional glucagon receptor activity means its full profile may differ in ways that phase 3 data will clarify
Non-human studies have suggested that BPC-157 supports a healthy gut
Still, authors suggested that it is more likely to be due to the short median follow-up time and the high proportion of Censored patients
The Lancet paper came out in 2026
May 12, 2025 - 2025 Provider Manual Our Provider manual has been updated for 2025 and is now available on our website at As a reminder, the Provider Manual provides in-depth plan/product information on topics such as: Product/Benefit details for each Jefferson Health Plans product (Health Partners Plans Medicaid, Health Partners Plans CHIP, Jefferson Health Plans Medicare Advantage, Jefferson Health Plans Individual and Family) Utilization, Quality Management and Clinical Programs Billing and Reimbursement regulations Guidelines for complaints, grievances and appeals Compliance requirements Much more
